Peter Ertl,
Professor of Lab-on-a-Chip Systems,
Vienna University of Technology
Prof. Ertl holds an engineering degree in Biotechnology (University of Life Sciences, BOKU, Austria), a PhD in Chemistry (University of Waterloo, UW, Canada) and received his postdoctoral training as a biophysicist at University of California at Berkeley (UCB, US). Following a position as Director of Product Development at a UW spin-off venture (Canada), Dr. Ertl joint the Biosensor Technology unit at the Austrian Institute of Technology (AIT). During his tenure at the AIT, Dr. Ertl was also granted a Fulbright Visiting Scholarship at UC Berkeley (2012) and conducted visiting scientist positions at Nanyang Technological University, Singapore (2013), the Medical Center of the University of California at San Francisco (2014). In 2016 he was appointed Professor of Lab-on-a-Chip Systems for Bioscience Technologies at the Vienna University of Technology (TUW), where his research focuses on the development of advanced in vitro diagnostic microsystems and organ-on-a-chip systems. Additionally, Dr Ertl held a visiting research appointment at Imperial College London (UK) in 2019 , is speaker of the Austrian Microfluidics Initiative (AMI) and editor of the open access journal Organs-on-a-Chip (Elsevier).
Joint-on-a-Chip: Monitoring the Onset and Progression of Inflammatory Responses in a Personalized Rheumatoid Arthritis Model
Wednesday, 9 September 2020 at 14:00
Add to Calendar ▼2020-09-09 14:00:002020-09-09 15:00:00Europe/LondonJoint-on-a-Chip: Monitoring the Onset and Progression of Inflammatory Responses in a Personalized Rheumatoid Arthritis ModelOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Rheumatoid arthritis is an autoimmune disease that causes inflamed joints through recruitment of immune cells, synovitis as well as degradation of cartilage. As a result, patients suffer from intense joint pain, are limited in their daily activities and have a lower life expectancy. To date almost 1% of the population worldwide is affected by arthritis, but no cure is available and pain reduction remains the treatment of choice. Although a number of drugs have shown to decrease disease progression, remission is achieved in less than 50% of patients, indicating a patient-specific drug response. Consequently, a personalized disease model is urgently needed to identify suitable drug combinations and concentrations for each individual patient. In this presentation the development of a sensor-integrated joint-on-a-chip platform capable of mimicking the physiological environment of a human diarthrodial joint is presented and observed patient variability discussed.
Add to Calendar ▼2020-09-09 00:00:002020-09-10 00:00:00Europe/LondonOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020Organ-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2020-09-09 14:00:002020-09-09 15:00:00Europe/LondonJoint-on-a-Chip: Monitoring the Onset and Progression of Inflammatory Responses in a Personalized Rheumatoid Arthritis ModelOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
